These 4 names are making big strides in treatments and vaccines for the the coronavirus.
Read MoreTrade Setup Buy Target $3.91 Sell Target $5.11 ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer.
Read MoreTrade Setup Buy Target $7.55 Sell Target $10.14 Aravive, Inc., a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the […]
Read MorePlus, the Senate passed its $2 trillion coronavirus stimulus package, deaths from COVID-19 surpassed 1,000 in the U.S., and Wendy’s withdrew guidance for the year.
Read MoreTrade Setup Buy Target $60.15 Sell Target $70.57 Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor […]
Read MoreAt the beginning of my career in the financial industry, I was a licensed rep for one of the largest mutual fund and discount brokerage companies in North America. Looking over the mutual funds that we offered, and digging into their respective investment philosophies was something I found to be really fascinating. It wasn’t just […]
Read MoreBuy Target – $11.50 or better Sell Target – TradersPro Sell Signal BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered […]
Read MoreTrade Setup Buy Target $4.59 Sell Target $5.88 Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase Ib clinical trials for advanced hematologic […]
Read MorePlus, the Fed issued new initiatives in an effort to calm the market, the Senate is still negotiating a $2 trillion stimulus package, GE’s aviation unit is laying off 10% of its workforce, and CVS is hiring 50,000 workers.
Read MoreThis company saw a 50% surge in visits last week, and that’s very good news for the stock.
Read MoreTrade Setup Buy Target $19.59 Sell Target $23.41 Karyopharm Therapeutics Inc., an oncology-focused pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit […]
Read MorePlus, airlines could be in danger, and Regeneron and Sanofi are soon to begin human trials on a treatment for COVID-19.
Read MoreTrade Setup Buy Target $2.22 Sell Target $2.92 Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company’s lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis.
Read MorePlus, Boeing said it had more cancellations than new orders in February, and Pepsi is buying Rockstar Energy.
Read MoreTrade Setup Buy Target $7.25 Sell Target $7.85 Ardelyx, Inc., a specialized biopharmaceutical company, develops and sells medicines for the treatment of cardio renal diseases in the United States and internationally. The company’s lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with […]
Read More